| Basics |
Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
|
| IPO Date: |
May 10, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$20.72M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.27%
|
| Avg Daily Range (30 D): |
$0.01 | 3.54%
|
| Avg Daily Range (90 D): |
$0.02 | 4.80%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
.38M |
| Avg Daily Volume (90 D): |
.32M |
| Trade Size |
| Avg Trade Size (Sh.): |
193 |
| Avg Trade Size (Sh.) (30 D): |
369 |
| Avg Trade Size (Sh.) (90 D): |
307 |
| Institutional Trades |
| Total Inst.Trades: |
112 |
| Avg Inst. Trade: |
$2.13M |
| Avg Inst. Trade (30 D): |
$.59M |
| Avg Inst. Trade (90 D): |
$.59M |
| Avg Inst. Trade Volume: |
.48M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.5M |
| Avg Closing Trade (30 D): |
$.6M |
| Avg Closing Trade (90 D): |
$.6M |
| Avg Closing Volume: |
712.2K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$ .13M
|
$ .08M
|
$ .57M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -10.24M
|
$ -9.25M
|
$ -26.43M
|
|
Operating Income / Loss
|
$ -12.55M
|
$ -10.72M
|
$ -61.89M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -5.17M
|
$ 11.28M
|
$ -.74M
|
|
PE Ratio
|
|
|
|
|
